

Chemical Market Reporter

October 8, 2001

SECTION: No. 13, Vol. 260; Pg. 15 ; ISSN: 1092-0110

IAC-ACC-NO: 79250376

LENGTH: 51 words

HEADLINE: SCHERING AG; acquired rights for Refludan; Brief Article

BODY:

SCHERING AG has acquired the worldwide rights for Refludan((lepirudin (rDNA) injection) from Aventis. Aventis had to divest the drug as a condition of the merger of Rhone Poulenc Rorer and Hoechst Marion Roussel. Ferghana Partners, a life sciences investment banking group, handled the divestment.

IAC-CREATE-DATE: October 19, 2001